We want to help improve the lives and futures of children on the autism spectrum
Wolfgang Storf, CEO, Neurotech International Ltd.
We want to improve people’s lives by developing and commercialising innovative, high quality medical solutions for the diagnosis and treatment of brain-related disorders.
The AAT Research group of companies is a fully owned subsidiary of Neurotech International Limited, an Australian public company (ASX:NTI). We research, design, develop and manufacture quality medical solutions. With regulatory and quality systems in place and various international accreditations to our name, our purpose is to improve people’s lives though innovation in the field of neuroscience and medical technology. Our mission is to be a global leader in the field of neurophysiology by offering solutions suitable for home-use and clinics at affordable prices.
For further information on Neurotech, please click here.
To improve the lives of people with neurological conditions.
To become a global leader in home-use and clinical neurotechnology solutions, which are accessible and affordable.
Our commitment to Quality
Commitment to the effectiveness of its QMS per regulatory requirements, whilst continuously improving the research and efficiency of its present and future medical devices.
To be team players, show care and compassion and to always communicate freely, clearly and respectfully.
To strive to achieve more than what is expected and to deliver what we promise without compromising quality or integrity.
To give highest priority to customer satisfaction and listen to customers and their needs.
To respect oneself and others, pushing for honesty, integrity and trust among colleagues.
Wolfgang Storf joined AAT Research in 2016 as chief executive officer. Prior to that, he was chief strategy officer with the MS Pharma Group. He was also CEO of Novartis-Sandoz in South Africa and held other senior management positions with Novartis-Sandoz, Apotex and Johnson & Johnson in different regions of the world. Wolfgang is a seasoned senior executive with proven global strategic and execution leadership experience – covering both commercial and technical operations as well R&D responsibility inside multinational and private businesses in the pharmaceutical and medical industry. He has a highly successful record of entering new markets, leading company turnarounds and effectively managing crisis missions. He also has experience in post-merger integration programs in both branded / un-branded markets. He has wide-ranging product expertise covering key chronic and acute TAs (solid / injectable) with focus on differentiation, as well biosimilar & OTC.
Dr Emanuela Russo joined Neurotech in 2016 as Head of Scientific and Clinical Research. Prior to that, she was Adjunct Professor “Niccolò Cusano” University of Rome. Dr Russo is a cognitive neuroscientist and a clinical psychologist. In her role she oversees the scientific activities and coordinates researches and clinical studies relevant to product’s development and scientific background. She graduated in Clinical Psychology and has a doctorate in Cognitive Psychology and Psychophysiology from the “Sapienza” University of Rome. Her research interests regard the brain correlates of attention and perception as well as the neural patterns underpinning cognitive-emotional states. She is specialized in the brain activity and its utilization as a clinical investigational tool for the evaluation of brain dysfunction. She is focused in the identification of biomarkers within broad categories of disorders (anxiety disorders, depression, ADHD, ASD) and how these indices can be remarkable in the prediction of treatment outcomes and in the development of neuromodulation interventions. In 2012, she received the ‘Best Young Researcher’ award at the IOP Congress in Pisa (Italy). She has held various positions as lecturer and Adjunct Professor since 2008. She has also been a reviewer for a several scientific journals.
Ing. Anabel Cutajar joined Neurotech in November 2016 as Head of Regulatory and Quality. Prior to that she was responsible for laboratory testing and systems in the automotive industry; during this period she was involved in all aspects related to process and production improvements, technical cleanliness requirements and customer/supplier relations. As Head of Quality & Regulatory, she is responsible for regulatory and quality matters with a focus on CE certification, ISO 13485 standard requirements as well as market entry with the respective regulatory requirements. She is working with external expert consultants on the company’s upcoming FDA submission. An engineer by profession, she has extensive experience in project management, testing principles, production and operations requirements and Quality Management system implementations and assurance. Ms Cutajar has a Bachelor’s degree in Electrical Engineering from the University of Malta.